CellCarta Strengthens its Histological Biomarker Franchise by Acquiring Artificial Intelligence-Based Quantitative Pathology Leader Reveal Biosciences

MONTREAL, May 11, 2021 /CNW Telbec/ - CellCarta, a global provider of precision medicine services, announced today the acquisition of Reveal Biosciences ("Reveal"), a San Diego California based computational pathology company offering cutting-edge artificial intelligence (AI)-based quantitative pathology and immunohistochemistry services to the biopharmaceutical industry. This acquisition further strengthens CellCarta's position as a leading provider of histopathology biomarker services and will enable the company to broaden its offering in AI-enabled multi-omic data analysis services and applications.

NewsGuest UserMay 11, 2021CellCarta, artificial intelligence, Reveal Biosciences

Valence Discovery Announces Multi-Target AI-Enabled Drug Design Collaboration with Servier

MONTREAL & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Valence Discovery (“Valence”), an emerging leader in AI-enabled drug design, announced today a multi-target discovery collaboration leveraging Valence’s platform for generative drug design with Servier, a global pharmaceutical company.

NewsGuest UserMarch 24, 2021Valence Discovery, Servier, Drug design, artificial intelligence

Canada and the United Kingdom collaborate on responsible artificial intelligence

Canada is a global leader in artificial intelligence (AI)—the single-largest transformative technology in the world. Fostering Canada’s advantage in digital technologies, including AI, is one of the pillars of the Government of Canada’s economic growth strategy.

NewsGuest UserMarch 12, 2020artificial intelligence, AI, Government of Canada

Five technologies that could disrupt pharma manufacturing

Pharma production is ‘too conservative’ and needs to ‘be bolder’ in adopting nascent technologies, or be left behind by new models, suggested one MD. An article from Ben Hargreaves